Page under construction!

The Randomised EuropeAn Celecoxib Trial (REACT) is a phase III multicentre double blind randomised trial of celecoxib versus placebo in primary breast cancer patients.

Coordinating groups: ICCG / GBG

Patients accrual
Study re-opened: January 2007
Closure date: October 2012
Target nr. of patients: 2590
Final accrual: 2590

Reason for closure: reached target accrual

To learn more, visit: http://www.germanbreastgroup.de/studien/adjuvant/react.html

• ClinicalTrials.gov Identifier: NCT02429427